Literature DB >> 23944376

Inflammasome and atherogenesis.

Xinjie Lu, Vijay Kakkar1.   

Abstract

Atherosclerosis is a progressive disease starting with accumulation of lipids, lipoproteins, and immune cells in the arterial wall. Inflammation and the innate immune response are involved in the formation of early atherosclerotic lesion. A protein complex known as the inflammasome is stimulated to activate interleukin-1β (IL-1β) and IL-18, which are responsible for activation of inflammatory processes. Inflammasome-mediated processes are important in the process of atherosclerosis. The front of structure domains as well as IL-1, and IL-18 stands at the threshold of the adaptive immune response that accelerates full-blown atherosclerotic disease progression. This review is intended to provide new insights into the pathogenesis of atherosclerosis and indicate new potential molecular targets for therapy of this disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23944376     DOI: 10.2174/13816128113199990586

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  11 in total

1.  Resveratrol alleviates vascular inflammatory injury by inhibiting inflammasome activation in rats with hypercholesterolemia and vitamin D2 treatment.

Authors:  Zu Yue Deng; Meng Mei Hu; Yan Fei Xin; Chen Gang
Journal:  Inflamm Res       Date:  2015-04-02       Impact factor: 4.575

Review 2.  Secretory leukocyte protease inhibitor promising protective roles in obesity-associated atherosclerosis.

Authors:  Qiao-Qing Zhong; Xiang Wang; Yun-Feng Li; Li-Jun Peng; Zhi-Sheng Jiang
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-04

3.  Ogg1-Dependent DNA Repair Regulates NLRP3 Inflammasome and Prevents Atherosclerosis.

Authors:  Gantsetseg Tumurkhuu; Kenichi Shimada; Jargalsaikhan Dagvadorj; Timothy R Crother; Wenxuan Zhang; Daniel Luthringer; Roberta A Gottlieb; Shuang Chen; Moshe Arditi
Journal:  Circ Res       Date:  2016-07-06       Impact factor: 17.367

Review 4.  IL-1β and IL-18: inflammatory markers or mediators of hypertension?

Authors:  S M Krishnan; C G Sobey; E Latz; A Mansell; G R Drummond
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

Review 5.  Recent insights into the cellular biology of atherosclerosis.

Authors:  Ira Tabas; Guillermo García-Cardeña; Gary K Owens
Journal:  J Cell Biol       Date:  2015-04-13       Impact factor: 10.539

Review 6.  The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of Atherosclerosis.

Authors:  Megan Yu; Sheng-Feng Tsai; Yu-Min Kuo
Journal:  Int J Mol Sci       Date:  2017-06-13       Impact factor: 5.923

Review 7.  Relationship Between Autophagy and Metabolic Syndrome Characteristics in the Pathogenesis of Atherosclerosis.

Authors:  Jing Xu; Munehiro Kitada; Yoshio Ogura; Daisuke Koya
Journal:  Front Cell Dev Biol       Date:  2021-04-15

8.  NALP3-Inflammasome-Related Gene Polymorphisms in Patients with Prehypertension and Coronary Atherosclerosis.

Authors:  Xin Zhao; Chonghuai Gu; Chenghui Yan; Xiaolin Zhang; Yi Li; Li Wang; Lili Ren; Yan Zhang; Junyin Peng; Zhiming Zhu; Yaling Han
Journal:  Biomed Res Int       Date:  2016-06-30       Impact factor: 3.411

9.  Study of the NLRP3 inflammasome component genes and downstream cytokines in patients with type 2 diabetes mellitus with carotid atherosclerosis.

Authors:  Junli Lee; Jing Wan; Linyun Lee; Changhua Peng; Hailong Xie; Chengbin Lee
Journal:  Lipids Health Dis       Date:  2017-11-18       Impact factor: 3.876

10.  The Enhanced Pharmacological Effects of Modified Traditional Chinese Medicine in Attenuation of Atherosclerosis Is Driven by Modulation of Gut Microbiota.

Authors:  Wenyan Ji; Ting Jiang; Zheng Sun; Fei Teng; Chenchen Ma; Shi Huang; Suhua Yan
Journal:  Front Pharmacol       Date:  2020-10-15       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.